# **Special Issue**

# Stem Cell as Tool for Drug Development

### Message from the Guest Editors

The key changes for drug discovery are the lack of adequate model systems and compound-screening tools. With recent advances in the culturing and differentiation of induced pluripotent stem cells (iPSCs). it is now possible to study human disease-specific cell types to identify disease mechanisms and to develop large-scale screens for drug discovery. One of the key challenges in developing effective drugs for neurodegenerative disorders is the lack of appropriate cellular models that accurately recapitulate the complexity of the human brain. This is where stem cells come into play. The use of stem cells in drug therapy for neurodegenerative disorders is important because it enables disease modeling, accelerates drug discovery, allows for personalized medicine approaches, provides insights into disease mechanisms, offers potential transplantation therapies, and ensures the safety of drug candidates. These advancements hold promise for the development of effective treatments that can slow disease progression, improve patient outcomes, and ultimately provide hope for individuals affected by neurodegenerative disorders.

### **Guest Editors**

Dr. Wenting Guo

French National Institute of Health and Medical Research, Inserm, France

### Dr. Pegah Masrori

- 1. Laboratory of Neurobiology, VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium
- 2. Department of Neurology, University Hospitals Leuven, Leuven, Belgium

### Deadline for manuscript submissions

closed (29 February 2024)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/177664

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

